T
TargEDys
Solutions to regulate appetite
About TargEDys
TargEDys is a pioneering company specializing in microbiome-based solutions aimed at weight management and optimal nutrition. Operating within the healthcare and biotechnology sectors, TargEDys collaborates with renowned researchers to develop precision probiotics that target specific health outcomes. The company's unique approach is backed by 10 families of patents, ensuring robust intellectual property protection. TargEDys primarily serves healthcare providers, nutritionists, and consumers seeking scientifically-backed nutritional supplements. The business model revolves around research and development, patent licensing, and direct sales of their probiotic products. Revenue is generated through product sales, partnerships, and licensing agreements. TargEDys' commitment to innovation and scientific rigor positions it as a leader in the next generation of probiotics.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- Longjumeau, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Seventure Partners
Pontifax Funds
NCI Information Systems
Bpifrance
Zaluvida
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TargEDys on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TargEDys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.